xenon xe-133

Small moleculeapprovedImaging agent

Approved

Oct 10, 1974

XENON XE-133 (Xenon-133) is an isotope of xenon. It is a radionuclide that is inhaled to assess pulmonary function, and to image the lungs. It is also used to image blood flow, particularly in the brain. Xenon Xe 133 diffuses easily, passing through cell membranes and exchanging freely between blood and tissue. It is distributed in the lungs in a manner similar to that of air, thus representing the regions of the lung that are aerated. The gamma photons of xenon Xe 133 can then be employed to obtain counts per minute per lung or region of the lung, or to display their distribution as a scan. Scintigraphs taken during the washout period, as the patient breathes room air, will show any obstruction in the airways as regions of radioactive gas trapping or retention. (In the presence of an abnormal or near normal Tc 99m albumin aggregated perfusion study, a normal ventilation study favors a diagnosis of pulmonary emboli. However, the presence of xenon Xe 133 gas trapping, during washout imaging, in areas of abnormal perfusion, favors a diagnosis of chronic-type obstructive pulmonary disease.) — NCATS

Clinical trial activity

37 trials · 40 clinical orgs · 4 marketing orgs

Phase 1
7
Phase 2
25
Phase 3
12
Phase 4
4

Earliest trial started Mar 1, 2004 (NCT00192959)

Timeline

1970s

  1. Oct 10, 1974

    Lantheus Medical Imaging — Earliest FDA Approval

  2. Oct 10, 1974

    Lantheus Medical Imaging — NDA Secondary Org

  3. Oct 10, 1974

    Lantheus Medical Imaging — NDA Organization

  4. Nov 16, 1976

    General Electric — NDA Secondary Org

1980s

  1. Mar 9, 1982

    Mallinckrodt — NDA Secondary Org

  2. Mar 9, 1982

    Curium Pharma — NDA Secondary Org

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • LungBINDING AGENT

    Lung binding agent

  • Unspecified targetOTHER

    Diagnostic agent

Approval history

  • approvedOct 10, 1974

Chemistry & pharmacology

Loading structure…

SMILES

[133Xe]
Mol. weight
132.90590566 g/mol
Chirality
Achiral Molecule
Inorganic
Yes
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only
Imaging
133-xenon

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • 133xe
  • 133xe
  • xe 133
  • xe-133
  • xe-133
  • xeneisol
  • xeneisol
  • xenon
  • xenon
  • xenon
  • xenon
  • xenon
  • xenon
  • xenon
  • xenon-133
  • xenon-133
  • xenon-133
  • xenon-133
  • xenon (133 xe)
  • xenon (133 xe)
  • xenon (133xe)
  • xenon (133xe)
  • xenon (133xe) gas
  • xenon (133xe) gas
  • xenon (133xe) gas
  • xenon (133xe) gas
  • xenon (133xe) gas
  • xenon (133xe) injection
  • xenon (133xe) injection
  • xenon (133xe) v.s.s.
  • xenon xe 133
  • xenon xe 133
  • xenon xe 133
  • xenon xe 133
  • xenon xe-133
  • xenon xe-133
  • xenon xe-133
  • xenon xe-133
  • xenon xe-133
  • xenon, xe-133
  • xenon, xe-133
  • xenon xe 133 gas ampule
  • xenon xe 133 gas vials

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03331302Phase 1/Phase 2 (Phase 2)Sep 1, 2018University of Virginia
NCT03418090Phase 3Aug 17, 2018Polarean Inc.
NCT03417687Phase 3Aug 17, 2018Polarean Inc.
NCT03176186Phase 3Oct 15, 2017NeuroproteXeon, Inc.
NCT03054870Phase 3Apr 1, 2017Certus International, Cyclomedica Australia PTY Limited
NCT02768727Phase 2Apr 1, 2016University of Pennsylvania
NCT02682758Phase 4Feb 1, 2016University of Duesseldorf
NCT02774096N/AFeb 1, 2016Capital Medical University
NCT02468531N/AJan 1, 2015Capital Medical University
NCT02220426Phase 1Sep 1, 2014University of North Carolina at Chapel Hill
NCT02129400Phase 3May 1, 2014RWTH Aachen University
NCT02071394Phase 2Mar 1, 2014University of Bristol
NCT02098148Phase 2Nov 1, 2013Mclean Hospital
NCT01839084Phase 3Jul 1, 2013German Research Foundation, RWTH Aachen University
NCT01948765Phase 2Jun 1, 2013Katholieke Universiteit Leuven
NCT01832363Phase 1/Phase 2 (Phase 2)Mar 1, 2013National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), University of Virginia, Washington University in St. Louis, Xemed LLC
NCT01757106Phase 2Dec 1, 2012Katholieke Universiteit Leuven
NCT01696630Phase 2Oct 1, 2012Centre Leon Berard
NCT01458639Phase 3Aug 1, 2012Certus International, Columbia University, Cyclomedica Australia PTY Limited, Washington University in St. Louis
NCT01545271Phase 1/Phase 2 (Phase 2)May 1, 2012University of Bristol
Showing 20 of 37 trials
Page 1 / 2

Organizations

Research & Development (40)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Air LiquideFor profit7642008
RWTH Aachen UniversityAcademic/Hospital6532008
University of VirginiaAcademic/Hospital3112011
Capital Medical UniversityAcademic/Hospital2212015
Centre Hospitalier Universitaire de NīmesAcademic/Hospital2222010
Certus InternationalFor profit2012012
Cyclomedica Australia PTY LimitedFor profit2212012
German Research FoundationAcademic/Hospital2012011
Katholieke Universiteit LeuvenAcademic/Hospital2212012
National Heart, Lung, and Blood Institute (NHLBI)Government2012011
National Institutes of Health (NIH)Government2012011
Polarean Inc.For profit2212018
University of BristolAcademic/Hospital2212012
University of DuesseldorfAcademic/Hospital2122010
University of ParisAcademic/Hospital2022009
Washington University in St. LouisAcademic/Hospital2022012
Xemed LLCFor profit2212011
BIOMNISFor profit1012010
Centre Leon BerardAcademic/Hospital1112012
Columbia UniversityAcademic/Hospital1012012
40 organizations
Page 1 / 2

Marketing (6)

OrganizationOrg typeRelationshipDate
Curium PharmaFor profitNDA2Mar 9, 1982
General ElectricFor profitNDA2Nov 16, 1976
General ElectricFor profitSYNMar 24, 1976
Lantheus Medical ImagingFor profitNDA2Oct 10, 1974
Lantheus Medical ImagingFor profitNDAOct 10, 1974
MallinckrodtFor profitNDA2Mar 9, 1982